BACKGROUND: Recent data strongly suggest that human leukocyte antigen (HLA) mismatching has a negative impact on development of bronchiolitis obliterans syndrome (BOS) and survival after lung transplantation (LTx). Because HLA matching is sometimes achieved by extending ischemic time in other solid-organ transplantation models and ischemic time is a risk factor per se for death after LTx, we sought to compare the theoretical benefit of HLA matching with the negative impact of lengthened ischemic time. METHODS: In this collaborative study we compared the relative impact of HLA mismatching and ischemic time on BOS and survival in 182 LTx recipients. RESULTS: Using multivariate analyses, we observed a lower incidence of BOS (hazard ratio [HR] = 1.70, 95% confidence interval [CI]: 1.1 to 2.7, p = 0.03) and enhanced survival (HR = 1.91, 95% CI: 1.24 to 2.92, p = 0.01) in patients with zero or one HLA-A mismatch compared with those having two HLA-A mismatches. This beneficial effect on survival was equivalent to a reduction of ischemic time of 168 minutes. CONCLUSIONS: We observed a reduced incidence of BOS and a better survival rate in patients well-matched at the HLA-A locus, associated with an opposite effect of an enhanced ischemic time. This suggests that graft ischemic time should be taken into account in future studies of prospective HLA matching in LTx.
BACKGROUND: Recent data strongly suggest that human leukocyte antigen (HLA) mismatching has a negative impact on development of bronchiolitis obliterans syndrome (BOS) and survival after lung transplantation (LTx). Because HLA matching is sometimes achieved by extending ischemic time in other solid-organ transplantation models and ischemic time is a risk factor per se for death after LTx, we sought to compare the theoretical benefit of HLA matching with the negative impact of lengthened ischemic time. METHODS: In this collaborative study we compared the relative impact of HLA mismatching and ischemic time on BOS and survival in 182 LTx recipients. RESULTS: Using multivariate analyses, we observed a lower incidence of BOS (hazard ratio [HR] = 1.70, 95% confidence interval [CI]: 1.1 to 2.7, p = 0.03) and enhanced survival (HR = 1.91, 95% CI: 1.24 to 2.92, p = 0.01) in patients with zero or one HLA-A mismatch compared with those having two HLA-A mismatches. This beneficial effect on survival was equivalent to a reduction of ischemic time of 168 minutes. CONCLUSIONS: We observed a reduced incidence of BOS and a better survival rate in patients well-matched at the HLA-A locus, associated with an opposite effect of an enhanced ischemic time. This suggests that graft ischemic time should be taken into account in future studies of prospective HLA matching in LTx.
Authors: Don Hayes; Bryan A Whitson; Samir N Ghadiali; Joseph D Tobias; Heidi M Mansour; Sylvester M Black Journal: Lung Date: 2015-07-29 Impact factor: 2.584
Authors: Don Hayes; Robert S Higgins; Ahmet Kilic; Stephen Kirkby; Amy L Pope-Harman; Thomas J Preston; Bryan A Whitson Journal: Lung Date: 2014-05-10 Impact factor: 2.584
Authors: Ha Eun Kim; Young Ho Yang; Hyo Chae Paik; Su Jin Jeong; Song Yee Kim; Moo Suk Park; Jin Gu Lee Journal: J Korean Med Sci Date: 2022-06-06 Impact factor: 5.354
Authors: Ji Eun Park; Chi Young Kim; Moo Suk Park; Joo Han Song; Young Sam Kim; Jin Gu Lee; Hyo Chae Paik; Song Yee Kim Journal: BMC Pulm Med Date: 2018-03-12 Impact factor: 3.317
Authors: Christopher Bricogne; Neil Halliday; Raymond Fernando; Emmanuel A Tsochatzis; Brian R Davidson; Mark Harber; Rachel H Westbrook Journal: Liver Transpl Date: 2022-05-04 Impact factor: 6.112
Authors: Thi H O Nguyen; Glen P Westall; Tara E Bull; Aislin C Meehan; Nicole A Mifsud; Tom C Kotsimbos Journal: PLoS One Date: 2013-02-06 Impact factor: 3.240